{"id":740195,"date":"2023-03-15T07:33:46","date_gmt":"2023-03-15T11:33:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/"},"modified":"2023-03-15T07:33:46","modified_gmt":"2023-03-15T11:33:46","slug":"navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/","title":{"rendered":"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update<\/b><\/p>\n<p class=\"bwalignc\"><i>Conference Call to be Held on Tuesday, March 21, 2023 at 5:00 p.m. (EDT)<\/i><\/p>\n<p>DUBLIN, Ohio&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nNavidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Tuesday, March 21, 2023 at 5:00 p.m. (EDT) to discuss corporate developments and financial results for the fourth quarter and full year ended December 31, 2022.\n<\/p>\n<p>\nDr. Michael Rosol, Chief Medical Officer, and Erika Eves, Vice President of Finance and Administration, will host the call and webcast to discuss the financial results and provide an update on recent developments and clinical progress. Management will be available to answer questions live immediately following the earnings announcement and prepared remarks portion of the call.\n<\/p>\n<p>\nTo participate in the call and webcast, please refer to the information below:\n<\/p>\n<p>\nEvent: Fourth Quarter 2022 Earnings Conference Call and Business Update<br \/>\n<br \/>Date: Tuesday, March 21, 2023<br \/>\n<br \/>Time: 5:00 p.m. (EDT)<br \/>\n<br \/>U.S. &amp; Canada Dial-In: 877-407-0312<br \/>\n<br \/>International Dial-In: +1 201-389-0899<br \/>\n<br \/>Conference ID: 13736745<br \/>\n<br \/>Webcast Link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.webcast-eqs.com%2Fnavidbioph20230321%2Fen&amp;esheet=53362302&amp;newsitemid=20230315005347&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.webcast-eqs.com%2Fnavidbioph20230321%2Fen&amp;index=1&amp;md5=a95e83b03f1fc27797b4a590e1c54f63\">https:\/\/www.webcast-eqs.com\/navidbioph20230321\/en<\/a><\/p>\n<p>\nA live audio webcast of the conference call will also be available on the investor relations page of Navidea\u2019s corporate website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.navidea.com&amp;esheet=53362302&amp;newsitemid=20230315005347&amp;lan=en-US&amp;anchor=www.navidea.com&amp;index=2&amp;md5=fe29c436c1655b583b48d52c327799ed\">www.navidea.com<\/a>. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea\u2019s website.\n<\/p>\n<p><b>About Navidea<\/b><\/p>\n<p>\nNavidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea\u2019s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea\u2019s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company\u2019s pipeline through global partnering and commercialization efforts. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.navidea.com&amp;esheet=53362302&amp;newsitemid=20230315005347&amp;lan=en-US&amp;anchor=www.navidea.com&amp;index=3&amp;md5=615744d081ec615f5c5c0d7540f15955\">www.navidea.com<\/a>.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at <span class=\"bwuline\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=53362302&amp;newsitemid=20230315005347&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.sec.gov&amp;index=4&amp;md5=88631ca7ccefd2e91992383b0b914250\">http:\/\/www.sec.gov<\/a><\/span> or at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fir.navidea.com&amp;esheet=53362302&amp;newsitemid=20230315005347&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.navidea.com&amp;index=5&amp;md5=e87f8b8d4a4eb43785f7b74a5d721d6f\">http:\/\/ir.navidea.com<\/a>.\n<\/p>\n<p>\nInvestors are urged to consider statements that include the words \u201cwill,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cplan,\u201d \u201ccontinue,\u201d \u201cdesigned,\u201d \u201cgoal,\u201d \u201cforecast,\u201d \u201cfuture,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cproject,\u201d and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.\n<\/p>\n<p>\nYou are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230315005347r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230315005347\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230315005347\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations Contact<br \/>\n<\/b><br \/>Navidea Biopharmaceuticals, Inc.<br \/>\n<br \/>Jeffrey Smith<br \/>\n<br \/>Vice President of Operations<br \/>\n<br \/>614-822-2365<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jsmith@navidea.com\">jsmith@navidea.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> New York Ohio United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230315005347\/en\/389794\/3\/navidea_cmyk.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update Conference Call to be Held on Tuesday, March 21, 2023 at 5:00 p.m. (EDT) DUBLIN, Ohio&#8211;(BUSINESS WIRE)&#8211; Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Tuesday, March 21, 2023 at 5:00 p.m. (EDT) to discuss corporate developments and financial results for the fourth quarter and full year ended December 31, 2022. Dr. Michael Rosol, Chief Medical Officer, and Erika Eves, Vice President of Finance and Administration, will host the call and webcast to discuss the financial results and provide an update on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740195","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update Conference Call to be Held on Tuesday, March 21, 2023 at 5:00 p.m. (EDT) DUBLIN, Ohio&#8211;(BUSINESS WIRE)&#8211; Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Tuesday, March 21, 2023 at 5:00 p.m. (EDT) to discuss corporate developments and financial results for the fourth quarter and full year ended December 31, 2022. Dr. Michael Rosol, Chief Medical Officer, and Erika Eves, Vice President of Finance and Administration, will host the call and webcast to discuss the financial results and provide an update on &hellip; Continue reading &quot;Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-15T11:33:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230315005347r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update\",\"datePublished\":\"2023-03-15T11:33:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\\\/\"},\"wordCount\":807,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230315005347r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\\\/\",\"name\":\"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230315005347r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-03-15T11:33:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230315005347r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230315005347r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/","og_locale":"en_US","og_type":"article","og_title":"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update - Market Newsdesk","og_description":"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update Conference Call to be Held on Tuesday, March 21, 2023 at 5:00 p.m. (EDT) DUBLIN, Ohio&#8211;(BUSINESS WIRE)&#8211; Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Tuesday, March 21, 2023 at 5:00 p.m. (EDT) to discuss corporate developments and financial results for the fourth quarter and full year ended December 31, 2022. Dr. Michael Rosol, Chief Medical Officer, and Erika Eves, Vice President of Finance and Administration, will host the call and webcast to discuss the financial results and provide an update on &hellip; Continue reading \"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-15T11:33:46+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230315005347r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update","datePublished":"2023-03-15T11:33:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/"},"wordCount":807,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230315005347r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/","name":"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230315005347r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-03-15T11:33:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230315005347r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230315005347r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/navidea-biopharmaceuticals-to-host-fourth-quarter-2022-earnings-conference-call-and-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740195"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740195\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}